Literature DB >> 8842419

Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils.

S Satoh1, I Ikegaki, Y Suzuki, T Asano, M Shibuya, H Hidaka.   

Abstract

1. The neuroprotective properties of fasudil (HA1077), a novel protein kinase inhibitor, were evaluated in two animal models of cerebral ischaemia: transient bilateral carotid artery occlusion in Mongolian gerbils and cerebral microembolization in rats. 2. The cytoprotective effect of fasudil on delayed neuronal death in gerbils was compared with the effects of nimodipine, a calcium channel antagonist and ozagrel, a thromboxane A2 synthetase inhibitor. The average of the neuronal cell density in the ischaemic control group was 17.8 +/- 2.1 cells mm-1, whereas fasudil (30 mg kg-1) significantly diminished the loss of CA1 neurones with the average of the neuronal cell density of 101.0 +/- 22.0 cells mm-1; nimodipine (10 mg kg-1) and ozagrel (30 mg kg-1) did not significantly protect against the ischaemia-induced neuronal loss. 3. In the rat model, the effects of fasudil on the histological and neurological consequences of cerebral microembolization produced via the injection of microspheres were examined. Twenty-four hours after the injection of microspheres into the internal carotid artery, all animals in the control group showed typical symptoms of stroke. Neurological function was significantly improved in the fasudil-treated animals. In the controls, the infarcted area in a cortical slice selected to include the hippocampal area was 0.25 +/- 0.01 cm2 (mean +/- s.e.mean) (43.9 +/- 2.4% of cortical section of the half hemisphere); the difference was significant compared to the mean area of 32.7 +/- 2.8 and 21.5 +/- 4.8% observed in rats treated with fasudil (3, 10 mg kg-1), respectively. Fasudil (10 mg kg-1) significantly suppressed the increased water content in ischaemic brain tissues (saline-treated rats, 82.4 +/- 0.2% vs fasudil-treated rats, 81.0 +/- 0.4%). 4. These results suggest that: (i) various protein kinases are involved in the pathogenesis of ischaemic injury; and (ii) the inhibition of protein kinases may be efficacious in preventing neuronal death, thus improving neurological function in the brain damage associated with ischaemic stroke.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842419      PMCID: PMC1909837          DOI: 10.1111/j.1476-5381.1996.tb15579.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Nicardipine reduces ischemic brain injury. Magnetic resonance imaging/spectroscopy study in cats.

Authors:  J Kucharczyk; W Chew; N Derugin; M Moseley; C Rollin; I Berry; D Norman
Journal:  Stroke       Date:  1989-02       Impact factor: 7.914

2.  Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade.

Authors:  K Maiese; J Wagner; L Boccone
Journal:  Neurosci Lett       Date:  1994-01-17       Impact factor: 3.046

3.  Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877.

Authors:  M Ohtaki; B Tranmer
Journal:  Stroke       Date:  1994-06       Impact factor: 7.914

4.  Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats.

Authors:  M Chopp; R L Zhang; H Chen; Y Li; N Jiang; J R Rusche
Journal:  Stroke       Date:  1994-04       Impact factor: 7.914

5.  The therapeutic value of nimodipine in experimental focal cerebral ischemia. Neurological outcome and histopathological findings.

Authors:  I M Germano; H M Bartkowski; M E Cassel; L H Pitts
Journal:  J Neurosurg       Date:  1987-07       Impact factor: 5.115

6.  Mechanism of action of a novel antivasospasm drug, HA1077.

Authors:  T Asano; I Ikegaki; S Satoh; Y Suzuki; M Shibuya; M Takayasu; H Hidaka
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

7.  The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats.

Authors:  M Tsuchiya; K Sako; Y Yonemasu; T Asano
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

8.  Protein kinase activity in canine basilar arteries after subarachnoid hemorrhage.

Authors:  Y Suzuki; M Shibuya; M Takayasu; T Asano; I Ikegaki; S Satoh; M Saito; H Hidaka
Journal:  Neurosurgery       Date:  1988-06       Impact factor: 4.654

9.  Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil.

Authors:  B J Alps; C Calder; W K Hass; A D Wilson
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

10.  Selective inhibition of myosin phosphorylation and tension of hyperplastic arteries by the kinase inhibitor HA1077.

Authors:  M Seto; K Shindo; K Ito; Y Sasaki
Journal:  Eur J Pharmacol       Date:  1995-03-24       Impact factor: 4.432

View more
  13 in total

Review 1.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

2.  Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.

Authors:  Siu-Lung Chan; Marilyn J Cipolla
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-30       Impact factor: 6.200

Review 3.  Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.

Authors:  Federico Carbone; Priscila Camillo Teixeira; Vincent Braunersreuther; François Mach; Nicolas Vuilleumier; Fabrizio Montecucco
Journal:  Antioxid Redox Signal       Date:  2014-04-22       Impact factor: 8.401

4.  Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.

Authors:  Yoshiyuki Rikitake; Hyung-Hwan Kim; Zhihong Huang; Minoru Seto; Kazuo Yano; Toshio Asano; Michael A Moskowitz; James K Liao
Journal:  Stroke       Date:  2005-09-01       Impact factor: 7.914

5.  Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.

Authors:  Hwa Kyoung Shin; Salvatore Salomone; E Michelle Potts; Sae-Won Lee; Eric Millican; Kensuke Noma; Paul L Huang; David A Boas; James K Liao; Michael A Moskowitz; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-11       Impact factor: 6.200

6.  Serum-borne bioactivity caused by pulmonary multiwalled carbon nanotubes induces neuroinflammation via blood-brain barrier impairment.

Authors:  Mario J Aragon; Lauren Topper; Christina R Tyler; Bethany Sanchez; Katherine Zychowski; Tamara Young; Guy Herbert; Pamela Hall; Aaron Erdely; Tracy Eye; Lindsey Bishop; Samantha A Saunders; Pretal P Muldoon; Andrew K Ottens; Matthew J Campen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

7.  Involvement of Rho-kinase in experimental vascular endothelial dysfunction.

Authors:  Dhvanit I Shah; Manjeet Singh
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

8.  Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats.

Authors:  Maha Mohammed Abdel-Fattah; Basim Anwar Shehata Messiha; Ahmed Mohamed Mansour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-17       Impact factor: 3.000

9.  Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia.

Authors:  Eduardo Candelario-Jalil; Armando González-Falcón; Michel García-Cabrera; Dalia Alvarez; Said Al-Dalain; Gregorio Martínez; Olga Sonia León; Joe E Springer
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

10.  Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase.

Authors:  Lin Huang; Zhi He; Lianjun Guo; Hongxing Wang
Journal:  Cell Mol Neurobiol       Date:  2007-06-07       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.